Azione 002940 ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Azioni

002940

CNE100003GC2

Prezzo di chiusura Shenzhen S.E.
Altri mercati azionari
 00:00:00 07/06/2024 		Variaz. 5gg Var. 1 gen.
15,76 CNY +2,40% Grafico intraday di Zhejiang AngLiKang Pharmaceutical CO.,LTD. -9,27% -27,41%
26/04 Zhejiang AngLiKang Pharmaceutical CO.,LTD. Riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024 CI
06/02 Anglikang Pharmaceutical firma un accordo di licenza per il farmaco tumorale di Affinity Biomedical MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!
Registrazione 100% gratuita
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on Share A for the Year 2023, Payable on June 17, 2024
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares.
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan.
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates
Anglikang Pharmaceutical Registers Metabolism Disorder Drug in China
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Approves Final Cash Dividend for 2022
Anglikang Pharma Signs Five-Year Purchase Agreement With European Firm
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2022
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022
Anglikang Pharma’s Drug to Lower Hypertension Fails to Make It on China’s Drug Procurement List
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione 002940
  4. Notizie Zhejiang AngLiKang Pharmaceutical CO.,LTD.
  5. Altre lingue